

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
50-793

MICROBIOLOGY REVIEW

Product Quality Microbiology Review

Consult Review for HFD-510

25 August 2003

NDA: 21-625
21-643

Drug Product Name:

Proprietary: M.V.I. Adult™ Pharmacy Bulk Package (NDA 21-643)

M.V.I. Adult™ for infusion (NDA 21-625)

Non-proprietary: Multi-vitamin for infusion

Drug Product Classification: Parenteral

Review Number: 1

Subject of this Review:

Submission Date: 12 March 2003 and 17 April 2003

Receipt Date: 13 March 2003 and 21 April 2003

Consult Date: 25 March 2003 and 28 April 2003

Date Assigned for Review: 01 May 2003

Applicant/Sponsor:

Name: AstraZeneca, LP

Address: 1800 Concord Pike, P.O. Box 8355, Wilmington, DE 19803

Representative: Kevin McKenna

Telephone: (302) 886-2742

Name of Reviewer: Paul Stinavage

Conclusion: The application is recommended for approval on the basis of sterility assurance.

Product Quality Microbiology Data Sheet

- A.
1. **TYPE OF SUPPLEMENT:** Not Applicable
 2. **SUPPLEMENT PROVIDES FOR:** Not Applicable
 3. **MANUFACTURING SITE:** Westborough, MA
 4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:** for intravenous administration
 5. **METHOD(S) OF STERILIZATION:**
 6. **PHARMACOLOGIC CATEGORY:** The product is used for total parenteral nutrition.
- B. **SUPPORTING/RELATED DOCUMENTS:** NDA 08-809, NDA 18-920
- C. **REMARKS:** The submission seeks approval for a product reformulation and a pharmacy bulk package format for the product.

Filename: N21625.doc

Executive Summary

I. Recommendations

- A. Recommendation on Approvability** – The application is recommended for approval on the basis of sterility assurance
- B. Recommendation on Phase 4 Commitments and/or Agreements, if Approvable**
Not applicable

II. Summary of Microbiology Assessments

- A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology**
The product is
- B. Brief Description of Microbiology Deficiencies – None**

III. Administrative

- A. Reviewer's Signature** _____
- B. Endorsement Block**
Paul Stinavage/25 August 2003
P.H. Cooney/
- C. CC Block**
cc:
Original NDA 21-625 and NDA 21-643
HFD-510/Division File/NDA 21-625/NDA 21-643/E. Galliers



2 Page(s) Withheld

§ 552(b)(4) Trade Secret / Confidential

§ 552(b)(5) Deliberative Process

§ 552(b)(5) Draft Labeling

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Paul Stinavage
8/27/03 08:19:29 AM
MICROBIOLOGIST
Product reformulation and pharmacy bulk package.

Peter Cooney
8/27/03 01:36:14 PM
MICROBIOLOGIST